Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application Figure S1 : Analysis of controlled drug release of GML and OML. A. In vitro release profile of Oxaliplatin and OML at 37°Cin 5% glucose solution by the dialysis method. Each point represents the mean±SD and p≤0.05 was considered to be statistically significant; B. In vitro release profile of Gemcitabine and GML at 37°Cin 5% glucose solution by the dialysis method. Each point represents the mean±SD and p≤0.05 was considered t o be statistically significant. Figure S2 : Effects of GML, OML on platelets. Notes: A. Platelet-aggregation rates from seven different groups were shown. Here, group 1 is the control group (NS), in which platelets were treated with saline, whereas groups 2-7 are the platelets treated with GMLcontaining the following concentrations of gemicitabine: 0, 0.3, 0.6, 0.9, 1.2, 1.5, 1.8 mg/mL. B. Platelet-aggregation rates from seven different groups were shown. Here, group 1 is the control group (NS), in which platelets were treated with saline, whereas groups 2-7 are the platelets treated with OML containing the following concentrations of oxaliplatin: 0, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30 mg/mL. 
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